InVivo Therapeutics Stock Forecast, Price & News

Wall Street analysts have given InVivo Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but InVivo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

InVivo Therapeutics saw a increase in short interest in January. As of January 29th, there was short interest totaling 3,870,000 shares, an increase of 149.7% from the January 14th total of 1,550,000 shares. Based on an average daily volume of 4,990,000 shares, the days-to-cover ratio is currently 0.8 days.
View InVivo Therapeutics' Short Interest.

InVivo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for InVivo Therapeutics.

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) released its earnings results on Wednesday, May, 13th. The biotechnology company reported ($2.47) earnings per share for the quarter.
View InVivo Therapeutics' earnings history.

InVivo Therapeutics' stock was trading at $1.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVIV stock has decreased by 36.3% and is now trading at $1.02.
View which stocks have been most impacted by COVID-19.

InVivo Therapeutics's stock reverse split on Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 11th 2020. An investor that had 100 shares of InVivo Therapeutics stock prior to the reverse split would have 3 shares after the split.

Some companies that are related to InVivo Therapeutics include LENSAR (LNSR), Pro-Dex (PDEX), SANUWAVE Health (SNWV), Nephros (NEPH), Delcath Systems (DCTH), InspireMD (NSPR), Sensus Healthcare (SRTS), AIT Therapeutics (AITB), Plus Therapeutics (PSTV), Nephros (NEPHD), STRATA Skin Sciences (SSKN), Sintx Technologies (SINT), Daxor (DXR), Arch Therapeutics (ARTH) and Motus GI (MOTS).
View all of NVIV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), Apollo Investment (AINV), IVERIC bio (OPHT), OPKO Health (OPK) and Cardiff Oncology (TROV).

InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

InVivo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.53%).
View institutional ownership trends for InVivo Therapeutics.

NVIV stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for InVivo Therapeutics or or view top insider-buying stocks.

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVIV stock can currently be purchased for approximately $1.02.

InVivo Therapeutics has a market capitalization of $21.60 million.

InVivo Therapeutics employs 6 workers across the globe.

The official website for InVivo Therapeutics is www.invivotherapeutics.com.

InVivo Therapeutics is headquartered at ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139.

InVivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 863-5500 or via email at [email protected]